Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.

10.1002/jha2.548

Saved in:

Bibliographic Details
Main Authors:	Spencer, Andrew, Samoilova, Olga, Chng, Wee-Joo, Labotka, Richard, Li, Cong, Wu, Kwang-Wei, Saxena, Nakul, Yan, Xu, Lee, Jae Hoon, Beksac, Meral
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Article
Published:	Wiley 2023
Subjects:	emerging‐markets ixazomib multiple myeloma overall survival proteasome inhibitor
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/237497
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-237497
record_format	dspace
spelling	sg-nus-scholar.10635-2374972023-02-27T02:12:00Z Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial. Spencer, Andrew Samoilova, Olga Chng, Wee-Joo Labotka, Richard Li, Cong Wu, Kwang-Wei Saxena, Nakul Yan, Xu Lee, Jae Hoon Beksac, Meral CANCER SCIENCE INSTITUTE OF SINGAPORE emerging‐markets ixazomib multiple myeloma overall survival proteasome inhibitor 10.1002/jha2.548 EJHaem 3 4 1241-1251 2023-02-27T02:00:14Z 2023-02-27T02:00:14Z 2022-11 2023-02-25T11:43:39Z Article Spencer, Andrew, Samoilova, Olga, Chng, Wee-Joo, Labotka, Richard, Li, Cong, Wu, Kwang-Wei, Saxena, Nakul, Yan, Xu, Lee, Jae Hoon, Beksac, Meral (2022-11). Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.. EJHaem 3 (4) : 1241-1251. ScholarBank@NUS Repository. https://doi.org/10.1002/jha2.548 2688-6146 https://scholarbank.nus.edu.sg/handle/10635/237497 Wiley Elements
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	emerging‐markets ixazomib multiple myeloma overall survival proteasome inhibitor
spellingShingle	emerging‐markets ixazomib multiple myeloma overall survival proteasome inhibitor Spencer, Andrew Samoilova, Olga Chng, Wee-Joo Labotka, Richard Li, Cong Wu, Kwang-Wei Saxena, Nakul Yan, Xu Lee, Jae Hoon Beksac, Meral Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.
description	10.1002/jha2.548
author2	CANCER SCIENCE INSTITUTE OF SINGAPORE
author_facet	CANCER SCIENCE INSTITUTE OF SINGAPORE Spencer, Andrew Samoilova, Olga Chng, Wee-Joo Labotka, Richard Li, Cong Wu, Kwang-Wei Saxena, Nakul Yan, Xu Lee, Jae Hoon Beksac, Meral
format	Article
author	Spencer, Andrew Samoilova, Olga Chng, Wee-Joo Labotka, Richard Li, Cong Wu, Kwang-Wei Saxena, Nakul Yan, Xu Lee, Jae Hoon Beksac, Meral
author_sort	Spencer, Andrew
title	Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.
title_short	Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.
title_full	Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.
title_fullStr	Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.
title_full_unstemmed	Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.
title_sort	impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: analysis of the emerging-markets subgroup of the tourmaline-mm1 trial.
publisher	Wiley
publishDate	2023
url	https://scholarbank.nus.edu.sg/handle/10635/237497
_version_	1759058425756516352

Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.

Similar Items